Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106860 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT00106860 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 158 participants.
The verdict
NCT00106860, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and effectiveness of the experimental drug, a benzodiazepine drug, in long-term use and the effects on quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with anxiety disorder.
Interventions
- DRUG a benzodiazepine drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106860
The ClinicalTrials.gov registry entry for NCT00106860 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which a benzodiazepine drug is the first listed.
NCT00106860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106860 about?
NCT00106860 is a clinical study titled "A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder". The purpose of the study is to assess the safety and effectiveness of the experimental drug, a benzodiazepine drug, in long-term use and the effects on quality of life, social and occupational functioning, sleep, and daytime sedation in subjects with anxiety disorder.
What is the current status of trial NCT00106860?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2005-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00106860?
The interventions under investigation include: a benzodiazepine drug (DRUG).
Who is sponsoring clinical trial NCT00106860?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.